GLP-1R agonist Treatment of Bscl2-null Mouse model of CGL2

Data resulting from studying the potential therapeutic benefits of GLP-1R agonists (here liraglutide) in lipoatrophic diabetes. Here Seipin-deficient Bscl2 null mice, modelling Congenital Generalised Lipodystrophy Type 2 (CGL2) were treated acutely or for 14 days with liraglutide. Assessments of glucose tolerance, insulin tolerance, pyruvate tolerance were made as well as determination of changes to hepatic steatosis, insulin secretion, pancreas histology and appetite regulation.